Overview

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Biotie Therapies Inc.
Collaborators:
INC Research
Syneos Health
Treatments:
Rufinamide